OZEM - ETF AI Analysis
Top Page
Roundhill GLP-1 & Weight Loss ETF (OZEM)
Rating:54Neutral
Price Target:―
Positive Factors
Focused Exposure to Weight-Loss Theme
The ETF targets companies involved in GLP-1 and weight-loss treatments, giving investors direct exposure to a fast-growing area of health care.
Strong Performance From Key Holdings
Several major positions like Eli Lilly, Viking Therapeutics, CSPC Pharmaceutical Group, and Amgen have shown strong gains, helping support the fund’s recent results.
Global Health Care Diversification
Holdings spread across the U.S., Hong Kong, and Japan within health care reduce reliance on any single country’s regulatory or market environment.
Negative Factors
High Sector Concentration in Health Care
With most assets in health care, the fund is heavily exposed to industry-specific risks such as drug trial setbacks and regulatory changes.
Notable Underperforming Holdings
Some sizable positions like Kailera Therapeutics, Chugai Pharmaceutical, and Ascletis Pharma have shown weak performance, which can drag on overall returns.
Above-Average Expense Ratio
The fund’s relatively high fee means more of the returns go to costs, which can be a bigger concern if performance remains weak over time.
OZEM vs. SPDR S&P 500 ETF (SPY)
AUM65.42M
RegionGlobal
Expense Ratio0.59%
Beta0.76
IssuerRoundhill
Inception DateMay 21, 2024
Dividend Yield1.2%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume19,500
30 Day Avg. Volume23,243
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.43Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OZEM Summary
Roundhill GLP-1 & Weight Loss ETF (OZEM) focuses on companies working on weight-loss drugs and treatments, especially GLP-1 medicines used for obesity and related health issues. It doesn’t track a traditional index, but instead targets a specific theme in healthcare and biotech. The fund holds major drug makers like Novo Nordisk and Eli Lilly, along with smaller biotech firms, giving investors a mix of established names and potential up-and-comers. Someone might invest for long-term growth tied to rising demand for weight-loss treatments. A key risk is that it’s heavily concentrated in healthcare and can swing sharply with drug trial results, regulation, and market sentiment.
How much will it cost me?The Roundhill GLP-1 & Weight Loss ETF (OZEM) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a niche sector like pharmaceuticals and biotechnology, which requires more research and specialized management.
What would affect this ETF?The Roundhill GLP-1 & Weight Loss ETF could benefit from growing global demand for innovative health solutions, particularly in obesity and metabolic disorder treatments, as well as advancements in biotechnology and pharmaceuticals led by top holdings like Novo Nordisk and Eli Lilly. However, potential risks include regulatory hurdles, competition in the weight management sector, and broader economic challenges that may impact healthcare spending or innovation funding. Global exposure also means the ETF could be affected by geopolitical events or currency fluctuations.
OZEM Top 10 Holdings
OZEM is heavily anchored in a handful of GLP-1 powerhouses, with Novo Nordisk and Eli Lilly steering the ship as their shares keep rising over the past few months, giving the fund a strong core in obesity and diabetes treatments. Amgen and CSPC Pharmaceutical add more fuel to the rally with steady-to-rising momentum, while Pfizer is more of a steady plodder, not really hurting but not helping much either. On the flip side, Viking Therapeutics and especially Kailera look like weak links, dragging at the fund’s heels. Overall, this is a highly concentrated, globally diversified bet on weight-loss and metabolic health, but very much tied to a small group of big drug names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.63% | $8.22M | $1.18T | 76.40% | 72 Outperform | |
| Novo Nordisk | 11.98% | $7.80M | $208.39B | -17.97% | 73 Outperform | |
| Pfizer | 7.08% | $4.60M | $159.99B | 8.46% | 74 Outperform | |
| CSPC Pharmaceutical Group | 6.95% | $4.53M | HK$105.71B | -12.94% | 63 Neutral | |
| Viking Therapeutics | 4.95% | $3.22M | $3.95B | 30.35% | 53 Neutral | |
| Kailera Therapeutics, Inc. | 4.73% | $3.08M | $2.23B | ― | ― | |
| Amgen | 4.42% | $2.88M | $237.52B | 49.57% | 77 Outperform | |
| ― | 4.18% | $2.72M | ― | ― | ― | |
| Chugai Pharmaceutical Co | 4.16% | $2.71M | ¥11.54T | -7.44% | 74 Outperform | |
| Ascletis Pharma, Inc. | 3.90% | $2.54M | HK$10.53B | -32.52% | 54 Neutral |
OZEM Technical Analysis
Positive
―
Price Trends
32.63
Positive
31.91
Positive
32.67
Positive
Market Momentum
0.41
Negative
64.23
Neutral
75.16
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.15, equal to the 50-day MA of 32.63, and equal to the 200-day MA of 32.67, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 64.23 is Neutral, neither overbought nor oversold. The STOCH value of 75.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OZEM.
OZEM Peer Comparison
Comparison Results
Performance Comparison
OZEM
Roundhill GLP-1 & Weight Loss ETF
34.26
8.94
35.31%
PSIL
AdvisorShares Psychedelics ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents